WG
AQST icon

Winton Group’s Aquestive Therapeutics AQST Stock Holding History

Winton Group’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Buy
+50,400
New +$212K 0.01% 1007

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Winton Group's AQST Position: Q2 2026 in Review

Winton Group opened a new position in Aquestive Therapeutics (AQST) in Q2 2026: 50,400 shares worth $210K. The stake represents 0.01% of the portfolio and ranks #1007 among its holdings.

184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Winton Group held 50,400 shares of Aquestive Therapeutics worth $210K as of Q2 2026.
  • Aquestive Therapeutics was a new Winton Group position in Q2 2026.
  • Aquestive Therapeutics made up 0.01% of Winton Group's portfolio in Q2 2026, its #1007 holding.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.